Skip Navigation

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Brutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients 65 years of age with Chronic Lymphocytic Leukemia CLL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT01886872

Study #:
STUDY00000970

Start Date:
Jul 22, 2014

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT01886872

View Complete Trial Details & Eligibility at ClinicalTrials.gov